JP2023022326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023022326A5 JP2023022326A5 JP2022197763A JP2022197763A JP2023022326A5 JP 2023022326 A5 JP2023022326 A5 JP 2023022326A5 JP 2022197763 A JP2022197763 A JP 2022197763A JP 2022197763 A JP2022197763 A JP 2022197763A JP 2023022326 A5 JP2023022326 A5 JP 2023022326A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- human
- seq
- nucleotide sequence
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 44
- 125000003729 nucleotide group Chemical group 0.000 claims 44
- 108700026244 Open Reading Frames Proteins 0.000 claims 42
- 108020004999 messenger RNA Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- 108010065637 Interleukin-23 Proteins 0.000 claims 21
- 102000013264 Interleukin-23 Human genes 0.000 claims 21
- 101000998124 Homo sapiens Interleukin-36 gamma Proteins 0.000 claims 16
- 102000055226 human IL36G Human genes 0.000 claims 16
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 14
- 102000051450 human TNFSF4 Human genes 0.000 claims 14
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims 12
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 10
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims 9
- 229930182558 Sterol Natural products 0.000 claims 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 8
- 150000003904 phospholipids Chemical class 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 150000003432 sterols Chemical class 0.000 claims 8
- 235000003702 sterols Nutrition 0.000 claims 8
- 108091051828 miR-122 stem-loop Proteins 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 4
- 108091066112 miR-122-1 stem-loop Proteins 0.000 claims 4
- 108091057488 miR-122-2 stem-loop Proteins 0.000 claims 4
- 108091070501 miRNA Proteins 0.000 claims 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 3
- 229940045145 uridine Drugs 0.000 claims 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical group O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- 108091007780 MiR-122 Proteins 0.000 claims 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 2
- -1 amino lipid Chemical class 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
Applications Claiming Priority (26)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338496P | 2016-05-18 | 2016-05-18 | |
| US201662338467P | 2016-05-18 | 2016-05-18 | |
| US201662338483P | 2016-05-18 | 2016-05-18 | |
| US201662338506P | 2016-05-18 | 2016-05-18 | |
| US62/338,467 | 2016-05-18 | ||
| US62/338,496 | 2016-05-18 | ||
| US62/338,506 | 2016-05-18 | ||
| US62/338,483 | 2016-05-18 | ||
| US201662404173P | 2016-10-04 | 2016-10-04 | |
| US201662404175P | 2016-10-04 | 2016-10-04 | |
| US62/404,173 | 2016-10-04 | ||
| US62/404,175 | 2016-10-04 | ||
| US201662415424P | 2016-10-31 | 2016-10-31 | |
| US62/415,424 | 2016-10-31 | ||
| US201662438942P | 2016-12-23 | 2016-12-23 | |
| US201662438945P | 2016-12-23 | 2016-12-23 | |
| US62/438,942 | 2016-12-23 | ||
| US62/438,945 | 2016-12-23 | ||
| US201762443693P | 2017-01-07 | 2017-01-07 | |
| US62/443,693 | 2017-01-07 | ||
| US201762472513P | 2017-03-16 | 2017-03-16 | |
| US62/472,513 | 2017-03-16 | ||
| US201762480400P | 2017-04-01 | 2017-04-01 | |
| US62/480,400 | 2017-04-01 | ||
| PCT/US2017/033395 WO2017201325A1 (en) | 2016-05-18 | 2017-05-18 | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| JP2018560868A JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560868A Division JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023022326A JP2023022326A (ja) | 2023-02-14 |
| JP2023022326A5 true JP2023022326A5 (https=) | 2023-05-09 |
| JP7586883B2 JP7586883B2 (ja) | 2024-11-19 |
Family
ID=59009786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560868A Active JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用 |
| JP2022197763A Active JP7586883B2 (ja) | 2016-05-18 | 2022-12-12 | 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560868A Active JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US10172808B2 (https=) |
| EP (2) | EP3458474B1 (https=) |
| JP (2) | JP7194594B2 (https=) |
| KR (2) | KR20230008243A (https=) |
| CN (2) | CN116726203A (https=) |
| AU (2) | AU2017266929B2 (https=) |
| CA (1) | CA3024917A1 (https=) |
| DK (1) | DK3458474T3 (https=) |
| ES (1) | ES2932516T3 (https=) |
| HR (1) | HRP20221135T8 (https=) |
| HU (1) | HUE059955T2 (https=) |
| LT (1) | LT3458474T (https=) |
| MA (1) | MA45035B1 (https=) |
| PL (1) | PL3458474T3 (https=) |
| PT (1) | PT3458474T (https=) |
| RS (1) | RS63625B1 (https=) |
| SI (1) | SI3458474T1 (https=) |
| SM (1) | SMT202300003T1 (https=) |
| WO (1) | WO2017201325A1 (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| RS63135B1 (sr) | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| EP3458474B1 (en) | 2016-05-18 | 2022-07-06 | ModernaTX, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| SMT202300097T1 (it) * | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| JP2021514190A (ja) * | 2018-02-19 | 2021-06-10 | コンバインド セラピューティクス インコーポレイテッドCombined Therapeutics, Inc. | コード化リボ核酸の器官保護発現および調節のための組成物および方法 |
| US11517530B2 (en) | 2017-09-27 | 2022-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic agents specifically delivered by exosomes for cancer treatment |
| EP3710020A4 (en) | 2017-11-14 | 2021-06-23 | Memorial Sloan-Kettering Cancer Center | IL-36 SECRETING IMMUNE RESPONSIVE CELLS AND USES THEREOF |
| CN110055275A (zh) * | 2018-01-19 | 2019-07-26 | 科济生物医药(上海)有限公司 | 一种质粒载体对、其修饰的免疫细胞及其应用 |
| WO2019143910A1 (en) * | 2018-01-22 | 2019-07-25 | Modernatx, Inc. | Multimeric polynucleotides and uses thereof |
| US20230081530A1 (en) * | 2018-09-14 | 2023-03-16 | Modernatx, Inc. | Methods and compositions for treating cancer using mrna therapeutics |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020097409A2 (en) * | 2018-11-08 | 2020-05-14 | Modernatx, Inc. | Use of mrna encoding ox40l to treat cancer in human patients |
| US12042527B2 (en) | 2019-01-08 | 2024-07-23 | Modernatx, Inc. | Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| KR20210141554A (ko) * | 2019-03-21 | 2021-11-23 | 코디악 바이오사이언시즈, 인크. | 세포외 소포 접합체 및 이의 용도 |
| US20220152085A1 (en) * | 2019-03-25 | 2022-05-19 | Ohio State Innovation Foundation | Combination immunoregulation and uses thereof |
| US20220162644A1 (en) * | 2019-05-29 | 2022-05-26 | Orbis Health Solutions, Llc | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
| US20220249389A1 (en) | 2019-07-12 | 2022-08-11 | Oregon Health & Science University | Immunotherapeutic constructs and methods of their use |
| WO2021011501A1 (en) | 2019-07-12 | 2021-01-21 | Oregon Health & Science University | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| BR112022004936A2 (pt) | 2019-09-19 | 2022-06-14 | Modernatx Inc | Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos |
| WO2021072172A1 (en) * | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| EP4045076A1 (en) | 2019-10-15 | 2022-08-24 | ModernaTX, Inc. | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| EP4132576A1 (en) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| JP7681617B2 (ja) | 2020-04-09 | 2025-05-22 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質ナノ粒子組成物 |
| JP2023526059A (ja) * | 2020-05-14 | 2023-06-20 | モダーナティエックス・インコーポレイテッド | mRNA治療薬及びエフェクター分子を含むLNP組成物 |
| EP4157319A1 (en) * | 2020-05-28 | 2023-04-05 | Modernatx, Inc. | Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer |
| WO2021262909A2 (en) | 2020-06-23 | 2021-12-30 | Modernatx, Inc. | Lnp compositions comprising mrna therapeutics with extended half-life |
| US11611540B2 (en) * | 2020-07-01 | 2023-03-21 | Vmware, Inc. | Protection of authentication data of a server cluster |
| CN111931428B (zh) * | 2020-07-06 | 2023-06-20 | 武汉第二船舶设计研究所(中国船舶重工集团公司第七一九研究所) | 一种用于优化海洋核动力平台的方法及系统 |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN114073677B (zh) * | 2020-08-20 | 2023-06-09 | 深圳深信生物科技有限公司 | 一种脂质纳米颗粒 |
| CN112516378B (zh) * | 2020-12-02 | 2022-02-11 | 浙江工业大学 | 一种植酸/丝素蛋白/煅烧白云石骨粘合剂的制备方法 |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| WO2022152939A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| JP2024506908A (ja) | 2021-02-12 | 2024-02-15 | モデルナティエックス インコーポレイテッド | インビボ療法のためのペイロードを含むlnp組成物 |
| US20240207444A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| US20240216288A1 (en) | 2021-03-24 | 2024-07-04 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| WO2022204370A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| WO2022266032A1 (en) * | 2021-06-14 | 2022-12-22 | Generation Bio Co. | Cationic lipids and compositions thereof |
| EP4355882A2 (en) | 2021-06-15 | 2024-04-24 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| CN115611757A (zh) * | 2021-07-16 | 2023-01-17 | 江苏慧聚药业股份有限公司 | mRNA传递剂的合成 |
| CN115703713B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| US20250017867A1 (en) | 2021-10-01 | 2025-01-16 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| WO2023056915A1 (en) * | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Polynucleotides encoding interleukin-12 (il-12) and related composition and methods thereof |
| CN114231624A (zh) * | 2021-10-28 | 2022-03-25 | 苏州大学附属第一医院 | 一种环状非编码rna在肾癌骨转移早期诊断及治疗中的应用 |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| WO2023077170A1 (en) | 2021-11-01 | 2023-05-04 | Modernatx, Inc. | Polynucleotides encoding integrin beta-6 and methods of use thereof |
| NL2030022B1 (en) | 2021-12-03 | 2023-06-21 | Wisdom Pharmaceutical Co Ltd | SYNTHESIS OF mRNA TRANSMITTER |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN115304756B (zh) * | 2022-01-30 | 2023-05-09 | 上海科技大学 | 一种五元脂质纳米颗粒及其制备方法和应用 |
| WO2023159197A1 (en) | 2022-02-18 | 2023-08-24 | Modernatx, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
| WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| CN119486749A (zh) * | 2022-06-22 | 2025-02-18 | 武汉厚先生物医药有限公司 | Il-12和ox40l组合物在肿瘤免疫治疗中的应用 |
| US20250388905A1 (en) * | 2022-07-10 | 2025-12-25 | Precigen, Inc. | POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION |
| US20260035707A1 (en) | 2022-07-26 | 2026-02-05 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
| JP2025534282A (ja) * | 2022-09-22 | 2025-10-15 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム | 新規分泌シグナルペプチド |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
| CN115671045B (zh) * | 2022-12-30 | 2023-04-07 | 华南理工大学 | 非肝靶向的核酸纳米制剂及其制备方法和应用 |
| WO2024182301A2 (en) | 2023-02-27 | 2024-09-06 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024206329A1 (en) | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof |
| EP4704816A1 (en) | 2023-05-03 | 2026-03-11 | ModernaTX, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| KR20260022409A (ko) * | 2023-06-09 | 2026-02-19 | 리누아진 바이오테크놀로지 씨오., 엘티디. | 발현 조절이 가능한 엔지니어링된 rna 분자 |
| WO2025184429A1 (en) | 2024-02-28 | 2025-09-04 | Modernatx, Inc. | Bromodomain and extra-terminal domain (bet) epigenetic reader decoy |
| WO2025231407A1 (en) * | 2024-05-03 | 2025-11-06 | Nutech Ventures | Lipid nanoparticles and methods of making and using |
| WO2025255199A1 (en) | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| US6140496A (en) | 1990-10-09 | 2000-10-31 | Benner; Steven Albert | Precursors for deoxyribonucleotides containing non-standard nucleosides |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| CA2326725A1 (en) | 1998-04-23 | 1999-10-28 | Takara Shuzo Co., Ltd. | Method for synthesizing dna |
| WO2000018778A1 (en) | 1998-09-29 | 2000-04-06 | Phylos, Inc. | Synthesis of codon randomized nucleic acids |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| US7384739B2 (en) | 2001-11-14 | 2008-06-10 | Toyo Boseki Kabushiki Kaisha | Compositions for enhancing DNA synthesis, DNA polymerase-related factors and utilization thereof |
| CA2409775C (en) | 2001-12-03 | 2010-07-13 | F. Hoffmann-La Roche Ag | Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro |
| US20040005600A1 (en) | 2002-04-01 | 2004-01-08 | Evelina Angov | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| US7550264B2 (en) | 2005-06-10 | 2009-06-23 | Datascope Investment Corporation | Methods and kits for sense RNA synthesis |
| KR20080025181A (ko) | 2005-06-30 | 2008-03-19 | 아케믹스 코포레이션 | 완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법 |
| US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US20080046192A1 (en) | 2006-08-16 | 2008-02-21 | Richard Lathrop | Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same |
| WO2008078180A2 (en) | 2006-12-22 | 2008-07-03 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| WO2009062102A2 (en) * | 2007-11-07 | 2009-05-14 | Genentech, Inc. | Compositions and methods for treatment of microbial disorders |
| WO2009075886A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
| AU2009238175C1 (en) * | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| CA2722183C (en) | 2008-04-25 | 2018-09-18 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
| US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
| US8126653B2 (en) | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| US8401798B2 (en) | 2008-06-06 | 2013-03-19 | Dna Twopointo, Inc. | Systems and methods for constructing frequency lookup tables for expression systems |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US20110082055A1 (en) | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| EP2619307A1 (en) | 2010-09-21 | 2013-07-31 | RiboxX GmbH | Method for synthesizing rna using dna template |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CA3101783C (en) * | 2011-10-11 | 2023-01-31 | Universitat Zurich Prorektorat Mnw | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| EP3466443B1 (en) | 2012-02-14 | 2020-12-16 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| SG10201912038TA (en) * | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| JP7348708B2 (ja) * | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
| RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| EP3458474B1 (en) | 2016-05-18 | 2022-07-06 | ModernaTX, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| KR102019331B1 (ko) | 2017-07-05 | 2019-09-09 | 한국과학기술연구원 | 모노포스포릴 지질 a를 구성적으로 생산하는 세균, 및 이를 이용한 모노포스포릴 지질 a 생산 방법 |
-
2017
- 2017-05-18 EP EP17727999.9A patent/EP3458474B1/en active Active
- 2017-05-18 LT LTEPPCT/US2017/033395T patent/LT3458474T/lt unknown
- 2017-05-18 KR KR1020227045735A patent/KR20230008243A/ko not_active Ceased
- 2017-05-18 SM SM20230003T patent/SMT202300003T1/it unknown
- 2017-05-18 KR KR1020187036733A patent/KR102482867B1/ko active Active
- 2017-05-18 CA CA3024917A patent/CA3024917A1/en active Pending
- 2017-05-18 DK DK17727999.9T patent/DK3458474T3/da active
- 2017-05-18 SI SI201731226T patent/SI3458474T1/sl unknown
- 2017-05-18 PL PL17727999.9T patent/PL3458474T3/pl unknown
- 2017-05-18 WO PCT/US2017/033395 patent/WO2017201325A1/en not_active Ceased
- 2017-05-18 EP EP22181855.2A patent/EP4137509A1/en not_active Withdrawn
- 2017-05-18 AU AU2017266929A patent/AU2017266929B2/en not_active Ceased
- 2017-05-18 CN CN202310702910.3A patent/CN116726203A/zh active Pending
- 2017-05-18 ES ES17727999T patent/ES2932516T3/es active Active
- 2017-05-18 JP JP2018560868A patent/JP7194594B2/ja active Active
- 2017-05-18 PT PT177279999T patent/PT3458474T/pt unknown
- 2017-05-18 RS RS20220929A patent/RS63625B1/sr unknown
- 2017-05-18 HR HRP20221135TT patent/HRP20221135T8/hr unknown
- 2017-05-18 MA MA45035A patent/MA45035B1/fr unknown
- 2017-05-18 CN CN201780044529.5A patent/CN109476718B/zh active Active
- 2017-05-18 HU HUE17727999A patent/HUE059955T2/hu unknown
-
2018
- 2018-06-01 US US15/995,889 patent/US10172808B2/en active Active
- 2018-11-08 US US16/184,282 patent/US10322090B2/en active Active
- 2018-12-13 US US16/219,418 patent/US10322091B2/en active Active
- 2018-12-17 US US16/222,155 patent/US10406113B2/en active Active
- 2018-12-20 US US16/227,810 patent/US10285950B2/en active Active
-
2019
- 2019-08-16 US US16/543,102 patent/US11185510B2/en active Active
-
2020
- 2020-10-15 US US17/071,685 patent/US11071716B2/en active Active
-
2021
- 2021-06-21 US US17/352,904 patent/US11344504B1/en active Active
-
2022
- 2022-05-27 US US17/826,387 patent/US20230041964A1/en not_active Abandoned
- 2022-09-07 US US17/930,369 patent/US11596609B2/en active Active
- 2022-12-12 JP JP2022197763A patent/JP7586883B2/ja active Active
-
2023
- 2023-08-03 AU AU2023210606A patent/AU2023210606A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023022326A5 (https=) | ||
| JP2022501336A5 (https=) | ||
| ES2625905T3 (es) | Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores | |
| JP2020536125A5 (https=) | ||
| JP2012097094A5 (https=) | ||
| JP2019516351A5 (https=) | ||
| EP3100718A1 (en) | Improved compositions and methods for the delivery of nucleic acids | |
| JP5277439B2 (ja) | 核酸内包高分子ミセル複合体 | |
| CN115778904B (zh) | 一种用于体外转染和体内递送mRNA的制剂 | |
| JP2020511521A (ja) | in vivoでの核酸発現のためのシステム及び方法 | |
| JPWO2022155524A5 (https=) | ||
| JP2004513075A5 (https=) | ||
| EP2950825B1 (en) | Functionalized dna dendrimers for gene delivery to cells | |
| JP2021517471A5 (https=) | ||
| JPWO2020056304A5 (https=) | ||
| JPWO2022120388A5 (https=) | ||
| CN116554125A (zh) | 一种阳离子脂质类似物、其组合物及应用 | |
| CN119074950A (zh) | 一种增强mRNA-LNP组织靶向递送的方法 | |
| JPWO2021178725A5 (https=) | ||
| AU2021350020A1 (en) | Systems and methods for expressing biomolecules in a subject | |
| JP2024534770A (ja) | 糖官能化核酸担体を含有するナノ粒子組成物 | |
| WO2025011593A1 (zh) | 一种用于预防猫泛白细胞减少症的疫苗及其制备方法和用途 | |
| JPWO2019169332A5 (https=) | ||
| WO2026002273A1 (zh) | 含氮链状化合物、制备方法、包含其的组合物和应用 | |
| CN117531012B (zh) | 一种基于dna佐剂水凝胶的肽疫苗及其制备方法和应用 |